Canaccord Genuity Group Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR)

Canaccord Genuity Group initiated coverage on shares of Kymera Therapeutics (NASDAQ:KYMR) in a report issued on Wednesday, MarketBeat.com reports. The firm set a “buy” rating and a $106.00 price target on the stock. Canaccord Genuity Group’s price target points to a potential upside of 28.16% from the stock’s current price.

Other equities analysts have also recently issued research reports about the company. Barclays lifted their target price on Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a research note on Tuesday, January 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Tuesday, April 21st. Jefferies Financial Group initiated coverage on Kymera Therapeutics in a research note on Monday, March 16th. They set a “buy” rating and a $110.00 target price on the stock. Morgan Stanley reaffirmed an “overweight” rating and set a $119.00 target price on shares of Kymera Therapeutics in a research note on Thursday, April 30th. Finally, Citigroup boosted their price target on Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $118.10.

Kymera Therapeutics Price Performance

NASDAQ:KYMR opened at $82.71 on Wednesday. Kymera Therapeutics has a fifty-two week low of $28.06 and a fifty-two week high of $103.00. The stock’s 50-day moving average is $84.42 and its two-hundred day moving average is $76.61. The stock has a market cap of $6.80 billion, a PE ratio of -23.17 and a beta of 2.06.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The company had revenue of $34.37 million for the quarter, compared to analysts’ expectations of $8.27 million. During the same quarter in the previous year, the business posted ($0.82) EPS. The business’s revenue for the quarter was up 55.5% on a year-over-year basis. On average, equities research analysts anticipate that Kymera Therapeutics will post -3.35 earnings per share for the current year.

Insider Transactions at Kymera Therapeutics

In related news, insider Noah Goodman sold 1,347 shares of the business’s stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $90.00, for a total value of $121,230.00. Following the completion of the sale, the insider owned 50,195 shares of the company’s stock, valued at approximately $4,517,550. The trade was a 2.61% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Jeremy G. Chadwick sold 300 shares of the business’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $90.00, for a total value of $27,000.00. Following the completion of the sale, the chief operating officer directly owned 61,202 shares of the company’s stock, valued at approximately $5,508,180. The trade was a 0.49% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 380,734 shares of company stock worth $32,193,902. 16.01% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Kymera Therapeutics

Several large investors have recently made changes to their positions in the company. Baker BROS. Advisors LP lifted its holdings in Kymera Therapeutics by 30.2% in the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after purchasing an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC lifted its holdings in Kymera Therapeutics by 17.7% in the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock worth $581,610,000 after purchasing an additional 1,124,747 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Kymera Therapeutics by 20.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after purchasing an additional 1,061,957 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after purchasing an additional 845,922 shares during the last quarter. Finally, Holocene Advisors LP acquired a new stake in Kymera Therapeutics in the 3rd quarter worth approximately $47,563,000.

Key Stories Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera presented new preclinical data showing KT‑579 (oral IRF5 degrader) produced activity comparable or superior to approved/clinically active therapies in IBD models — a meaningful R&D positive if confirmed in clinical studies. Article Title
• Positive Sentiment: Management will participate in multiple May investor conferences (fireside chats), increasing visibility with investors and analysts — typically supportive for sentiment and liquidity. Article Title
• Positive Sentiment: Q1 results and the accompanying presentation prompted analysts to lift estimates in some reports and coverage; positive analyst reaction to quarterly revenue and beats can support the stock. Article Title
• Neutral Sentiment: Kymera published its Q1 earnings presentation (details on pipeline progress, financials and guidance assumptions), useful for investors but not an immediate catalyst by itself. Article Title
• Neutral Sentiment: Company celebrated its 10‑year anniversary and rang the Nasdaq opening bell — PR/branding event with limited direct impact on valuation. Article Title
• Negative Sentiment: Brookline Capital Markets issued multiple model changes: they raised some near‑ and long‑term estimates (e.g., FY2026, FY2028–FY2030) but lowered Q3/Q4 2026 and FY2027 forecasts — the mixed/downgrade elements could weigh on sentiment by signaling slower expected progress or higher near‑term spend. Article Title

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.